Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets
Ipsen Q1 2019 sales growth of 17.0% as reported, or 15.8%1at constant exchange rates and consolidation scope.
Pharmaceuticals, Biotechnology and Life Sciences
Ipsen Q1 2019 sales growth of 17.0% as reported, or 15.8%1at constant exchange rates and consolidation scope.
Based on EpimAb’sglobally filed first application, this patent broadly covers bispecificantibodies obtained utilizing the company’s FIT-Ig®technology in a composition of matter claim.
HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products,…
Firm Continues Expansion of IP Practice with Two Patent Prosecutors DEL MAR, Calif.–(BUSINESS WIRE)–Sheppard Mullin is pleased to announce that…
Life science industry veterans Colleen Delaney, MD, MSc, Christopher Henney, PhD, Ron Howell, Steven Reed, PhD, to be honored during…
The round includes follow-on investment from Grazia Equity and Capnamic Ventures to provide easier access to more biotech products internationally…
Visit D2 Booth 501, Asembia Specialty Pharmacy Summit, April 29 – May 2, 2019, Las Vegas, NV ST. LOUIS–(BUSINESS WIRE)–As…
Molly Fishman Joins CLSA’s Washington, D.C. Office from the Staff of Representative Jackie Speier WASHINGTON & SAN FRANCISCO & SAN…
Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”
MARIETTA, Ohio–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AAGP?src=hash" target="_blank"gt;#AAGPlt;/agt;–ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) updates its stockholders regarding phase 3 of testing…